5.75
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Armata Pharmaceuticals Inc | ARMP | AMEX | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.00 | 0.0% | 5.75 | 04:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 5.75 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 5.75 | USD |
Armata Pharmaceuticals Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 107.54M | 18.70M | 5.31M | $ - | $ - | -2.66 | -2.30 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Armata Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ARMP Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.24 | 6.24 | 5.5001 | 5.87 | 18,902 | -0.49 | -7.85% |
| 1 Month | 3.79 | 10.48 | 3.34 | 5.32 | 102,348 | 1.96 | 51.72% |
| 3 Months | 3.25 | 10.48 | 2.56 | 4.55 | 55,255 | 2.50 | 76.92% |
| 6 Months | 3.25 | 10.48 | 2.56 | 4.20 | 33,725 | 2.50 | 76.92% |
| 1 Year | 3.88 | 10.48 | 2.52 | 3.97 | 26,833 | 1.87 | 48.2% |
| 3 Years | 4.90 | 10.48 | 2.45 | 4.19 | 55,656 | 0.85 | 17.35% |
| 5 Years | 4.90 | 10.48 | 2.45 | 4.19 | 55,656 | 0.85 | 17.35% |
Armata Pharmaceuticals Description
| Armata Pharmaceuticals Inc is a clinical-stage biotechnology company focused on improving human health through the development of novel natural and synthetic bacteriophage-based therapies to treat multidrug-resistant bacterial infections and preventable infectious diseases of the microbiome. Its product candidate, AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. |
